PATIENT INFORMATION LEAFLET Please read this leaflet Carefully This leaflet will tell you about Clarityn Allergy Syrup . It should give you all the informationyou need, but if there is anything you do not understand please ask your doctor or yourpharmacist. What is in Clarityn Allergy Syrup ? The syrup contains
Suomen sivusto, jossa voit ostaa halvalla ja laadukas Viagra http://osta-apteekki.com/ toimitus kaikkialle maailmaan.
Erityisesti laatu viagra tästä kaupasta voi taata henkilökohtaisesti cialis Paras laatu kehotan Teitä miellyttää.
Levofloxacin solution 02 leaflet - g2lafll02aespp.cdrLevofloxacin Ophthalmic Solution 0.5%
Levofloxacin Ophthalmic Solution 0.5% is a sterile topical ophthalmic solution. Levofloxacin is a fluoroquinolone
antibacterial active against a broad spectrum of Gram-positive and Gram-negative ocular pathogens. Levofloxacin is
the pure (-)-(s)-enantiomer of the racemic drug substance, ofloxacin. It is more soluble in water neutral pH than
Chemical Name: (-)-(s)-9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7Hpyrido [1,2,3-de]-1,4
benzoxazine-6-carboxylic acid hemihydrate. Levofloxacin (hemihydrate) is a yellowish-white crystalline powder. Each mL
of Levofloxacin Ophthalmic Solution contains 5.12 mg of levofloxacin hemihydrate equivalent to 5 mg levofloxacin.
Active: Levofloxacin 0.5% ( mg/mL); Preservative: benzalkonium chloride 0.005%;
Inactives: sodium chloride and water for injection. May also contain hydrochloric acid and/or sodium hydroxide to adjust pH.
Levofloxacin Ophthalmic Solution is isotonic and formulated at pH 6.5 with an osmolality of approximately 300 mOsm/kg.
Levofloxacin is a fluorinated 4-quinolone containing a six-member (pyridobenzoxazine) ring from positions 1 to 8 of the basic
Levofloxacin concentration in plasma was measured in 15 healthy adult volunteers at various time points during a 15 day
course of treatment with Levofloxacin Ophthalmic Solution. The mean levofloxacin concentration in plasma 1 hour postdose,
ranged from 0.86 ng/mL on Day 1 to 2.05 ng/mL on Day 15. The highest maximum mean levofloxacin concentration of
2.5 ng/mL was measured on Day 4 following 2 days of dosing every 2 hours for a total of 8 doses per day. Maximum mean
levofloxacin concentrations increased from 0.94 ng/mL on Day 1 to 2.15 ng/mL on Day 15, which is more than 1,000 times
lower than those reported after standard oral doses of levofloxacin. Levofloxacin concentration in tears was measured in 30
healthy adult volunteers at various time points following instillation of a single drop of Levofloxacin Ophthalmic Solution.
Mean levofloxacin concentrations in tears ranged from 34.9 to 221.1 µg/mL during the 60-minute period following the single
dose. The mean tear concentrations measured 4 and 6 hours postdose were 17.0 and 6.6 µg/mL. The clinical significance of
these concentrations is unknown.
Levofloxacin is the L-isomer of the racemate, ofloxacin, a quinolone antimicrobial agent. The antibacterial activity of ofloxacin
resides primarily in the L-isomer. The mechanism of action of levofloxacin and other fluoroquinolone antimicrobials involves
the inhibition of bacterial topoisomerase IV and DNA gyrase (both of which are type II topoismerases), enzymes required for
DNA replication, transcription, repair, and recombination. Levofloxacin has in vitro activity against a wide range of Gram-
negative and Gram-positive microorganisms and is often bactericidal at concentrations equal to or slightly greater than
Fluoroquinolones, including levofloxacin, differ in chemical structure and mode of action from â-lactam antibiotics and
aminoglycosides, and therefore may be active against bacteria resistant to â-lactam antibiotics and aminoglycosides.
Additionally, â-lactam antibiotics and aminoglycosides may be active against bacteria resistant to levofloxacin. Resistance to
levofloxacin due to spontaneous mutation in vitro is a rare occurrence (range: 10 to 10 ). Levofloxacin has been shown to be active against most strains of the following microorganisms, both in vitro and in clinical infections as described in the INDICATIONS AND USAGE section: AEROBIC GRAM-POSITIVE MICROORGANISMS
Streptococcus (Groups C/F)
Streptococcus (Group G)
Viridans group streptococci
AEROBIC GRAM-NEGATIVE MICROORGANISMS
*Efficacy for this organism was studied in fewer than 10 infections. The following in vitro data are also available, but their
clinical significance in ophthalmic infections is unknown. The safety and effectiveness of levofloxacin in treating
ophthalmological infections due to these microorganisms have not been established in adequate and well-controlled trials.
These organisms are considered susceptible when evaluated using systemic breakpoints. However, a correlation between
the in vitro systemic breakpoint and ophthalmological efficacy has not been established. The list of organisms is provided as
guidance only in assessing the potential treatment of conjunctival infections.
Levofloxacin exhibits in vitro minimal inhibitory concentrations (MICs) of 2µg/mL or less (systemic susceptible breakpoint)
against most (>90%) strains of the following ocular pathogens:
Aerobic gram-positive microorganisms
Aerobic gram-negative microorganisms
In randomized, double-masked, multicenter controlled clinical trial where patients were dosed for 5 days, Levofloxacin
Ophthalmic Solution demonstrated clinical cures in 79% of patients treated for bacterial conjunctivitis on the final study visit
day (day 6-10). Microbial outcome for the same clinical trials demonstrated an eradication rate for presumed pathogens of 90%.
INDICATIONS AND USAGE
Levofloxacin Ophthalmic Solution is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains
of the following organisms:
AEROBIC GRAM-POSITIVE MICROORGANISMS
Staphylococcus epidermidis Streptococcus pneumoniaeStreptococcus (Groups C/F)Streptococcus (Group G)Viridans group streptococci AEROBIC GRAM-NEGATIVE MICROORGANISMS
*Efficacy for this organism was studied in fewer than 10 infections.
Levofloxacin Ophthalmic Solution is contraindicated in patients with a history of hypersensitivity to levofloxacin, to other
quinolones, or to any of the components of this medication.
NOT FOR INJECTION. Levofloxacin Ophthalmic Solution should not be injected subconjunctially, nor should it be introduced
directly into the anterior chamber of the eye.
In patients receiving systemic quinolones, serious and occasionally fatal hypersensitivity (anaphylactic) reactions have been
reported, some following the first dose. Some reactions were accompanied by cardiovascular collapse, loss of
consciousness, angioedema (including laryngeal, pharyngeal or facial edema), airway obstruction, dyspnea, urticaria, and
itching. If an allergic reaction to levofloxacin occurs, discontinue the drug. Serious acute hypersensitivity reactions may
require immediate emergency treatment. Oxygen and airway management should be administered as clinically indicated.
As with other anti-infectives, prolonged use may result in overgrowth of non-susceptible organisms, including fungi. If
superinfection occurs, discontinue use and institute alternative therapy. Whenever clinical judgment dictates, the patient
should be examined with the aid of magnification, such as slitlamp biomicroscopy, and where appropriate, fluorescein
staining. Patients should be advised not to wear contact lenses if they have signs and symptoms of bacterial conjunctivitis.
Information for Patients
Avoid contaminating the applicator tip with material from the eye, fingers or other source. Systemic quinolones have been
associated with hypersensitivity reactions, even following a single dose. Discontinue use immediately and contact your
physician at the first sign of a rash or allergic reactions.
Specific drug interaction studies have not been conducted with Levofloxacin Ophthalmic Solution. However, the systemic
administration of some quinolones has been shown to elevate plasma concentrations of theophylline, interfere with the
metabolism of caffeine, and enhance the effects of the oral anticoagulant warfarin and its derivatives, and has been
associated with transient elevations in serum creatinine in patients receiving systemic cyclosporine concomitantly.
Carcinogenesis, Mutagenesis, Impairment of Fertility:
In a long term carcinogenicity study in rats, levofloxacin exhibited no carcinogenic or tumorigenic potential following daily
dietary administration; the highest dose (100 mg/kg/day) was 875 times the highest recommended human ophthalmic dose.
Levofloxacin was not mutagenic in the following assays: Ames bacterial mutation assay (S. typhimurium and E. coli),
CHO/HGPRT forward mutation assay, mouse micronucleus test, mouse dominant lethal test, rat unscheduled DNA
synthesis assay, and the in vivo mouse sister chromatid exchange assay. It was positive in the in vitro chromosomal
aberration (CHL cell line) and in vitro sister chromatid exchange (CHL/IU cell line) assays. Levofloxacin caused no
impairment of fertility or reproduction in rats at oral doses as high as 360 mg/kg/day, corresponding to 3,150 times the highest recommended human ophthalmic dose.
Pregnancy: Teratogenic Effects. Pregnancy Category C
Levofloxacin at oral doses of 810 mg/kg/day in rats, which corresponds to approximately 7,000 times the highest
recommended human ophthalmic dose, caused decreased fetal body weight and increased fetal mortality. No teratogenic
effect was observed when rabbits were dosed orally as high as 50 mg/kg/day, which corresponds to approximately 400 times
the highest recommended maximum human ophthalmic dose, or when dosed intravenously as high as 25 mg/kg/day,
corresponding to approximately 200 times the highest recommended human ophthalmic dose. There are, however, no
adequate and well-controlled studies in pregnant woman. Levofloxacin should be used during pregnancy only if the potential
benefit justifies the potential risk to the fetus.
Levofloxacin has not been measured in human milk. Based upon data from ofloxacin, it can be presumed that levofloxacin is
excreted in human milk. Caution should be exercised when Levofloxacin Ophthalmic Solution is administered to a nursing
Safety and effectiveness in infants below the age of one year have not been established. Oral administration of
quinolones has been shown to cause arthropathy in immature animals. There is no evidence that the ophthalmic
administration of levofloxacin has any effect on weight bearing joints.
No overall differences in safety or effectiveness have been observed between elderly and other adult patients.
The most frequently reported adverse events in the overall study populations were transient decreased vision,
fever, foreign body sensation, headache, transient ocular burning, ocular pain or discomfort, pharyngitis and
photophobia. These events occurred in approximately 1-3% of patients. Other reported reactions occurring in less
than 1% of patients included allergic reactions, lid edema, ocular dryness and ocular itching.
DOSAGE AND ADMINISTRATION
Days 1 and 2:
Instill one to two drops in the affected eye(s) every 2 hours while awake, up to 8 times per day.
Days 3 through 7:
Instill one to two drops in the affected eye(s) every 4 hours while awake, up to 4 times per day.
Levofloxacin Ophthalmic Solution 0.5% is supplied in a natural, low density polyethylene
bottle with a controlled dropper tip and a tan, high density polyethylene cap in the following size:
Bottles of 5 mL NDC 16571-150-50
Store at 20°-25°C (68°-77°F)
Manufactured in India for:Nexus Pharmaceuticals Inc.,Vernon Hills, IL 60061.
Distributed by: Pack Pharmaceuticals, LLC, Buffalo Grove, IL 60089.
Levofloxacin Ophthalmic Solution 0.5% Leaflet
Size: 125 (W) x 275 (H) mm
Pharma Code: Front : 185 Std. Back : 187 Std.
Edge Code : 6 x 5 mm
Publikationen - Auswahl der letzten 5 Jahre Peginterferon alfa-2a/ribavirin for 48 or 72 weeks in hepatitis C genotypes 1 and 4 patients with slow virologic response. Ferenci P, Laferl H, Scherzer TM, Maieron A, Hofer H, Stauber R, Gschwantler M, Brunner H, Wenisch C, Bischof M, Strasser M, Datz C, Vogel W, Löschenberger K, Steindl-Munda P; Gastroenterology. 2010 Feb;138(2):503-12,